
News|Articles|August 18, 2026
Closing the Gap: Innovation vs Access in Blood Cancer Care
Author(s)Maggie L. Shaw
Fact checked by: Laura Joszt, MA
Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.
Advertisement
Advertisement
Multiple myeloma was once described as a death sentence. Today, thanks to proteasome inhibitors, immunomodulatory drugs (IMiDs), anti-CD38 antibodies, and chimeric antigen receptor (CAR) T-cell therapy, patients are living years—sometimes decades—longer than previous survival estimates. Similar transformations are underway across
Related to this article

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.
Advertisement
Advertisement

